Jordi Molina Alsina, Investor Relations Manager at Almirall

Barcelona, 7 June 2007.- Almirall has appointed Jordi Molina Alsina as manager of the Investor Relations Department. This position was created after announcing 20 June as the proposed date for the company listing. Mr. Molina’s main mission is to liaise between the Spanish pharmaceutical company and the stock market stakeholders.

In this new position, Jordi Molina’s responsibilities will include facilitating the relationship between investors and analysts, together with institutions related with the activities of listed companies (Spanish Stock Exchange Commission, etc.)

Jordi Molina has a degree in Economics and Business Studies from the University of Barcelona and a degree in Politics and International Relations from the University of London. He has recently specialised in Corporate Finance. With more than ten years of experience working for Almirall, he has been responsible for Finance Management and Procurement in R&D and was currently Financial Controller for Corporate Projects.

Almirall

Almirall, a leading company committed to health, is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed drugs with the aim of improving people’s health and quality of life.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.

For more information:

Ketchum/SEIS

Tony Noel / Mónica Escusa

tony.noel@ketchum.com

monica.escusa@ketchum.com

Tel.: +34 91 788 32 00.- Fax: +34 91 788 32 99

Note

This document is a press release and not a prospectus. Investors should not therefore acquire or apply for any shares or other securities mentioned herein without having previously consulted the information contained within the official prospectus approved by the Spanish Securities Commission on 31 May. This prospectus is available to the public at the Spanish Securities Commission website (www.cnmv.es) and from the company itself (www.almirall.es).Copies of the official prospectus will also be available free of charge from company headquarters.

This document should in no way be construed as an offer or invitation to treat, nor does it represent an offer to buy or subscribe to shares in the Company. Likewise, the contents of this document and the fact that it has been distributed must not be used as, or form the basis for, any kind of contract or decision to invest and do not constitute any recommendation as regards the securities of the Company.

This communication is intended solely for people living outside the United Kingdom and may not be used by anybody living within that country.

The information contained herein does not constitute an offer of securities in the United States. Offers and sales of securities in the United States may not be made absent registration under the U.S. Securities Act of 1933, as amended, or an applicable exemption therefrom. This document does not solicit money, securities or any other type of consideration, and, if any money, securities or other type of consideration is sent in response hereto, it will not be accepted.

Finally, neither this document nor any copy thereof may be taken or transmitted to the United States of America, Canada, Australia or Japan or be distributed, either directly or indirectly, in the United States of America, Canada, Australia or Japan or given to residents of any of these countries.